- Home
- VIVO vs PLUR Comparison
VIVO vs PLUR Comparison
Compare VIVO & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VIVO | PLUR |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | United Kingdom | Israel |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.5M | 33.9M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | VIVO | PLUR |
|---|---|---|
| Price | $2.43 | $3.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | N/A | ★ 5.5K |
| Earning Date | 11-22-2022 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | N/A | $2.82 |
| 52 Week High | N/A | $7.13 |
Technical Indicators
Market Signals| Indicator | VIVO | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 36.22 |
| Support Level | N/A | $2.91 |
| Resistance Level | N/A | $3.42 |
| Average True Range (ATR) | 0.00 | 0.20 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 6.88 |
Price Performance
Historical ComparisonAbout PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.